NSIS B — Novozymes A/S Income Statement
0.000.00%
- DKK192.47bn
- DKK203.76bn
- €3.83bn
- 75
- 11
- 73
- 52
Annual income statement for Novozymes A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | fx Final | Final |
Revenue | |||||
Total Revenue | 1,880 | 2,011 | 2,360 | 2,403 | 3,834 |
Cost of Revenue | |||||
Gross Profit | 1,054 | 1,162 | 1,288 | 1,305 | 1,810 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,390 | 1,472 | 1,711 | 1,869 | 3,333 |
Operating Profit | 490 | 539 | 649 | 534 | 501 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 472 | 528 | 613 | 525 | 417 |
Provision for Income Taxes | |||||
Net Income After Taxes | 379 | 423 | 496 | 408 | 306 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 379 | 423 | 494 | 406 | 306 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 379 | 423 | 494 | 406 | 306 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.33 | 1.48 | 1.63 | 1.64 | 1 |
Dividends per Share |